XBIOTECH INC Reports Total Revenue of USD 0.0 Million in Q1 of FY 2023.

May 28, 2023

Earnings Overview

On May 10, 2023, XBIOTECH INC ($BER:4XB) released their financial results for the first quarter of fiscal year 2023, which ended on March 31, 2023. The total revenue for this period was USD 0.0 million, a decrease of 100.0% from the same period one year prior. Net income was USD -3.8 million, representing a decrease from -5.4 million in the previous year.

Stock Price

On Wednesday, XBIOTECH INC reported a total revenue of USD 0.0 Million for the first quarter of FY 2023. Despite the decrease in revenue, XBIOTECH INC stock opened at €3.0 and closed at €3.0, representing a 2.0% increase from the prior closing price of 3.0. XBIOTECH INC has attributed the decrease in revenue to challenging economic conditions caused by the global pandemic. The company is currently investing in its products and services to ensure its long-term sustainability.

XBIOTECH INC is also working to create new partnerships and establish new markets for its products in order to improve its financial performance. In spite of the current economic climate, XBIOTECH INC remains committed to delivering innovative products and services to its customers. With its investments and focus on creating new products and markets, XBIOTECH INC is optimistic that it will be able to achieve positive financial results in the coming quarters. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Xbiotech Inc. More…

    Total Revenues Net Income Net Margin
    3.51 -31.32 -829.0%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Xbiotech Inc. More…

    Operations Investing Financing
    -14.51 -63.74 0
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Xbiotech Inc. More…

    Total Assets Total Liabilities Book Value Per Share
    242.12 5.22 7.78
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Xbiotech Inc are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -34.8% -962.7%
    FCF Margin ROE ROA
    -425.6% -8.8% -8.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we recently conducted an analysis of XBIOTECH INC‘s wellbeing. Our results showed that XBIOTECH INC is a high risk investment in terms of financial and business aspects, scoring poorly on our Risk Rating. To provide our customers with a more detailed look at the company, we detected a couple of risk warnings, related to their income sheet and balance sheet. If you’d like to know more about this, make sure to register on goodwhale.com and take a look at our report. We strive to provide the most accurate and up-to-date information, so that our customers can make the best decisions for their investments. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Summary

    XBIOTECH INC has reported their financial results for the first quarter of FY 2023, with total revenue of USD 0.0 million and a net income of USD -3.8 million. Investors should take caution when considering investing in XBIOTECH INC, as the company has seen a significant drop in revenue and net income in the first quarter of FY 2023. It is important to monitor the company’s progress to assess if they can turn their financials around.

    Recent Posts

    Leave a Comment